prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 3643, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 1619
2021
-
Efektivita časné léčby COVID-19 kombinující remdesivir a rekonvalescentní plazmu s vysokým titrem u hematologických pacientů.
Year: 2021, type: Conference abstract
-
Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).
Year: 2021, type: Conference abstract
-
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients
LEUKEMIA & LYMPHOMA, year: 2021, volume: 62, edition: 5, DOI
-
Ex vivo fenotypizace a monitoring CD19 CAR-T lymfocytů: zkušenosti jednoho centra.
Year: 2021, type: Conference abstract
-
Fosforylace proteinu p53: vliv na aktivitu dráhy p53 po poškození DNA u chronické lymfocytární leukémie.
Year: 2021, type: Conference abstract
-
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia
Blood, year: 2021, volume: 138, edition: 9, DOI
-
FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia: Novel Therapeutic Target.
Year: 2021, type: Conference abstract
-
GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors.
Year: 2021, type: Conference abstract
-
GAB1 Regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia: novel therapeutic target
Year: 2021, type: Conference abstract
-
GAB1 reguluje tonickou AKT signalizaci a migraci buněk chronické lymfatické leukémie: implikace pro kombinační léčbu s BCR inhibitory.
Year: 2021, type: Conference abstract